Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > AGN , Facebook interview today

<< Previous

Bullboard Posts

Next >>

Comment by TheBearInTheWoodson Aug 18, 2020 9:49pm

149 Views

Post# 31426178

RE:AGN , Facebook interview today

I will say AGN market maker is doing a good job and promotion is continuous but they need help with webinars, look at the competition ....

https://t.co/JKBgyLNIgR?amp=1

they actually address the science and teach shareholders the mechanism of action vs pump. dont get me wrong money can be made here, just bringing awareness.

Mechanism of action + Patent + Drug Library = Pharma interest

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec